Guggenheim analyst Yatin Suneja reiterated a Buy rating and $170.00 price target on Praxis Precision Medicines Inc. (NASDAQ: PRAX).The analyst ...

This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE